Apremilast led to a 75% improvement in PPPASI-75 in a significant portion of patients by week 16, with these improvements maintained through week 52.

Cheever shared with Dermatology Times her excitement for educational opportunities, networking, and presentations from experts in the specialty.

Share with us the topics you want to learn more about at Elevate-Derm West.

The conference aimed at providing dermatology NPs and PAs with the latest in the specialty begins today in Scottsdale, Arizona.

These findings can help clinicians better treat the psychosocial factors associated with the disease.

We want to know: Will you be attending the conference in Scottsdale later this week?

The LIBERTY-AD PED-OLE study showed clinical remission for moderate to severe atopic dermatitis.

Christopher Bunick, MD, PhD, highlights rademikibart's next-generation efficacy, showing stronger IL-4Rα binding affinity in atopic dermatitis and asthma.

Dermatology Times asked our readers to share what conferences they are looking forward to in the fourth quarter of 2024.

Catch up on coverage from the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

At Fall Clinical 2024, Christopher Bunick, MD, PhD, presented findings on the prevalence of systemic corticosteroid use among patients with atopic dermatitis and highlighted how those treated with upadacitinib achieved and sustained optimal skin clearance and itch relief long-term.

Catch up on coverage from the final day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

Discover top innovations, insights, and clinical pearls from Fall Clinical in Las Vegas, where dermatology’s biggest breakthroughs took center stage.

Deucravacitinib demonstrated significant efficacy and safety in treating moderate to severe scalp psoriasis, as shown in the PSORIATYK SCALP trial presented at Fall Clinical.

At Fall Clinical 2024, Ablon shared her top device-based interventions, from wound care to radiofrequency rejuvenation, revealing clinical pearls for enhanced aesthetic outcomes.

At Fall Clinical 2024, Christopher Bunick, MD, PhD, discussed systemic therapy options and the importance of comprehensive treatment targets in managing atopic dermatitis, emphasizing AHEAD recommendations and LEVEL UP data.

At Fall Clinical 2024, Graber spotlighted precise acne-targeting lasers, new combination creams, and a promising rosacea pill awaiting FDA approval.

Song shared top clinical tips at Fall Clinical, covering alopecia areata, refractory dermatoses, and novel non-steroidal topicals.

The recent meta-analysis revealed comparable efficacy in treating acne vulgaris and was presented at Fall Clinical 2024.

Catch up on coverage from the third day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.